Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma proteins from cancer patients with weight loss.
We determined the circulating level of bioactivity for skeletal muscle proteolysis-inducing factors (PIF) in the blood samples from cancer patients whose body weight loss was greater than 10%. The level of bioactivity was estimated by measurement of tyrosine release from isolated 1at diaphragm muscles incubated with an ultrafiltered fraction of plasma or serum proteins containing molecules from 0 to 25 kDa in molecular weight. Significant levels of bioactivity were detected in 25 of the 50 cancer samples. No activity was found in 18 of the samples from healthy human blood donors. The ability of 13 of the cancer samples to induce muscle proteolysis was significantly inhibited by incubation of muscles in presence of indomethacin (10 microM). The neutralisation of 12 of the cancer samples with the antibodies to recombinant human interleukin-1 (IL-1), alpha and beta forms, partially abrogated the activity in five samples. These results suggest that the accelerated breakdown of proteins induced by the cancer plasma factors is at least in part mediated by IL-1 in cooperation with other active factors not yet defined. Additionally, we have shown that the increased breakdown of proteins induced by PIF in the crude supernatant derived from activated mouse peritoneal macrophages is prevented by the treatment of muscles with either indomethacin or quin-2 (1 microM). These observations provide indirect evidence for a possible causal relationship between the production of PIF and the body-weight loss of cancer patients.
Belizario
J E
JE
Centro de Biotecnologia, Instituto Butantan, São Paulo, Brazil.
Katz
M
M
Chenker
E
E
Raw
I
I
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001798:Blood Proteins / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D002100:Cachexia / Q000097:blood*; D002648:Child; D003964:Diaphragm / Q000378:metabolism; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D007375:Interleukin-1 / Q000032:analysis / Q000037:antagonists & inhibitors / Q000494:pharmacology; D008297:Male; D051379:Mice; D008875:Middle Aged; D008970:Molecular Weight; D009124:Muscle Proteins / Q000378:metabolism*; D009369:Neoplasms / Q000097:blood*; D051381:Rats; D011919:Rats, Inbred Strains; D011994:Recombinant Proteins / Q000032:analysis / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000493:pharmacokinetics; D015431:Weight Loss
D001798:Blood Proteins; D007375:Interleukin-1; D009124:Muscle Proteins; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D007213:Indomethacin